Citeline

Biotech Britain Vs. The World

Mar 9, 2026
Edison Brilliant Knowledge

Redesigning immunity: The next frontier in immuno-oncology

Feb 18, 2026
BioInsights

Role of supportive care in the future of cell therapies

Feb 4, 2026
Daily Mail

SMALL CAP MOVERS: Poolbeg Pharma

Jan 30, 2026
Frontiers

POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study

Jan 29, 2026
Drug Discovery World (DDW)

JPM 2026: Less talk and more action

Jan 28, 2026
Frontiers

POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study

Jan 23, 2026

Digna T. de Bruin, Manon A. A. Jansen, Diana R. Pereira, Lisa van Schijndel,…

Drug Discovery World (DDW)

DDW Winter 2025/2026

Jan 22, 2026
Citeline

Scrip Asks… What Does 2026 Hold For Biopharma? Part 1: Capital Allocation And Dealmaking

Jan 9, 2026
Business Post

Poolbeg expects several clinical trial results in 2026

Dec 18, 2025
Poolbeg Pharma
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.